Ratings for Hims & Hers Health HIMS were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 4 | 0 | 5 | 0 | 0 |
Last 30D | 1 | 0 | 0 | 0 | 0 |
1M Ago | 0 | 0 | 2 | 0 | 0 |
2M Ago | 1 | 0 | 3 | 0 | 0 |
3M Ago | 2 | 0 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $22.44, with a high estimate of $26.00 and a low estimate of $18.00. This upward trend is evident, with the current average reflecting a 36.75% increase from the previous average price target of $16.41.
Exploring Analyst Ratings: An In-Depth Overview
The standing of Hims & Hers Health among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Ryan MacDonald | Needham | Announces | Buy | $24.00 | - |
George Hill | Deutsche Bank | Raises | Hold | $23.00 | $16.00 |
Korinne Wolfmeyer | Piper Sandler | Maintains | Neutral | $18.00 | $18.00 |
Jailendra Singh | Truist Securities | Raises | Hold | $23.00 | $13.00 |
Jonna Kim | TD Cowen | Raises | Buy | $25.00 | $15.00 |
Korinne Wolfmeyer | Piper Sandler | Raises | Neutral | $18.00 | $16.00 |
Glen Santangelo | Jefferies | Raises | Hold | $23.00 | $14.00 |
Michael Cherny | B of A Securities | Raises | Buy | $26.00 | $22.00 |
Michael Cherny | B of A Securities | Raises | Buy | $22.00 | $17.25 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Hims & Hers Health. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Hims & Hers Health compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Hims & Hers Health's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Hims & Hers Health's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Hims & Hers Health analyst ratings.
About Hims & Hers Health
Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, primary care, and more.
Key Indicators: Hims & Hers Health's Financial Health
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Hims & Hers Health's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 51.82% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Hims & Hers Health's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 4.21%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Hims & Hers Health's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.76%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Hims & Hers Health's ROA excels beyond industry benchmarks, reaching 2.86%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.03.
What Are Analyst Ratings?
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.